Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.
Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, National University Health System, Singapore.
Aust Crit Care. 2022 Sep;35(5):520-526. doi: 10.1016/j.aucc.2021.08.001. Epub 2021 Sep 10.
Use of high-flow nasal cannula (HFNC) has become a regular intervention in the intensive care units especially in patients coming in with hypoxaemic respiratory failure. Clinical practices may differ from published literature.
The objective of this study was to determine the clinical practices of physicians and respiratory therapists (RTs) on the use of HFNC.
A retrospective observational study looking at medical records on HFNC usage from January 2015 to September 2017 was performed and was followed by a series of questions related to HFNC practices. The survey involved physicians and RTs in intensive care units from multiple centres in Singapore from January to April 2018. Indications and thresholds for HFNC usage with titration and weaning practices were compared with the retrospective observational study data.
One hundred twenty-three recipients (69.9%) responded to the survey and reported postextubation (87.8%), pneumonia in nonimmunocompromised (65.9%), and pneumonia in immunocompromised (61.8%) patients as the top three indications for HFNC. Of all, 39.8% of respondents wanted to use HFNC for palliative intent. Similar practices were observed in the retrospective study with the large cohort of 63% patients (483 of the total 768 patients) where HFNC was used for acute hypoxaemic respiratory failure and 274 (35.7%) patients to facilitate extubation. The survey suggested that respondents would initiate HFNC at a lower fraction of inspired oxygen (FiO), higher partial pressure of oxygen to FiO ratio, and higher oxygen saturation to FiO ratio for nonpneumonia patients than patients with pneumonia. RTs were less likely to start HFNC for patients suffering from pneumonia and interstitial lung disease than physicians. RTs also preferred adjustment of FiO to improve oxygen saturations and noninvasive ventilation for rescue.
Among the different intensive care units surveyed, the indications and thresholds for the initiation of HFNC differed in the clinical practices of physicians and RTs.
高流量鼻导管(HFNC)的使用已成为重症监护病房的常规干预措施,特别是在出现低氧性呼吸衰竭的患者中。临床实践可能与已发表的文献有所不同。
本研究旨在确定医生和呼吸治疗师(RT)在 HFNC 使用方面的临床实践。
进行了一项回顾性观察性研究,对 2015 年 1 月至 2017 年 9 月期间 HFNC 使用的病历进行了回顾,并随后提出了一系列与 HFNC 实践相关的问题。该调查于 2018 年 1 月至 4 月期间涉及新加坡多家中心的重症监护病房的医生和 RT。HFNC 使用的适应证和阈值以及滴定和撤机实践与回顾性观察性研究数据进行了比较。
共有 123 名(69.9%)受访者对调查做出了回应,并报告了拔管后(87.8%)、非免疫功能低下患者的肺炎(65.9%)和免疫功能低下患者的肺炎(61.8%)是 HFNC 的前三大适应证。在所有受访者中,有 39.8%的人希望将 HFNC 用于姑息治疗。在对 63%的患者(768 名患者中的 483 名)进行的大型队列回顾性研究中也观察到了类似的实践,其中 274 名(35.7%)患者使用 HFNC 来治疗急性低氧性呼吸衰竭,274 名(35.7%)患者用于辅助拔管。调查表明,与肺炎患者相比,非肺炎患者的受访者更倾向于以较低的吸入氧分数(FiO)、较高的氧分压与 FiO 比值和较高的氧饱和度与 FiO 比值开始 HFNC。RT 不太可能为肺炎和间质性肺疾病患者启动 HFNC,而医生则更有可能。RT 还更喜欢调整 FiO 以改善氧饱和度和使用无创通气进行抢救。
在所调查的不同重症监护病房中,医生和 RT 在 HFNC 启动的适应证和阈值方面的临床实践存在差异。